Clinical Outcomes and Racial Disparities in Metastatic Hormone‐Sensitive Prostate Cancer in the Era...
Clinical Outcomes and Racial Disparities in Metastatic Hormone‐Sensitive Prostate Cancer in the Era of Novel Treatment Options
About this item
Full title
Author / Creator
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Docetaxel (DOC) and abiraterone (ABI) in the upfront setting have separately improved clinical outcomes for metastatic hormone‐sensitive prostate cancer (mHSPC), but there are no studies comparing drug efficacies or the influence of racial disparities.
Materials and Methods
We performed a retrospective multicenter review from Wi...
Alternative Titles
Full title
Clinical Outcomes and Racial Disparities in Metastatic Hormone‐Sensitive Prostate Cancer in the Era of Novel Treatment Options
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8571757
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8571757
Other Identifiers
ISSN
1083-7159
E-ISSN
1549-490X
DOI
10.1002/onco.13848
